Literature DB >> 3018044

Role of plasma gelsolin and the vitamin D-binding protein in clearing actin from the circulation.

S E Lind, D B Smith, P A Janmey, T P Stossel.   

Abstract

We determined the plasma kinetics of both actin and complexes of actin with the two high affinity actin-binding proteins of plasma, gelsolin, and vitamin D-binding protein (DBP). Actin is cleared rapidly from the plasma by the liver (half-disappearance time, 0.5 h). Using radiolabeled actin-binding proteins, we found that actin accelerated the clearance of both plasma gelsolin and the vitamin D-binding protein. In separate experiments we found that DBP-actin complexes were cleared more quickly than gelsolin-actin complexes, at a rate comparable to the clearance of actin from the blood. A low affinity interaction (dissociation constant, 2.9 X 10(-4) M) between actin and fibronectin was found, suggesting that little actin will bind to fibronectin in plasma. We conclude that while plasma gelsolin and DBP may both clear actin from the circulation, DBP appears to play a more important role. By so doing, DBP may conserve the filament-severing activity of plasma gelsolin.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3018044      PMCID: PMC423663          DOI: 10.1172/JCI112634

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

1.  On the interaction of F-actin with fibrin.

Authors:  K Laki; L Muszbek
Journal:  Biochim Biophys Acta       Date:  1974-12-18

2.  Evidence of increased Gc:actin complexes in pregnant serum: a possible result of trophoblast embolism.

Authors:  D L Emerson; P Arnaud; R M Galbraith
Journal:  Am J Reprod Immunol       Date:  1983-12       Impact factor: 3.886

3.  Molecular properties of radioiodinated apolipoprotein A-I.

Authors:  J C Osborne; E J Schaefer; G M Powell; N S Lee; L A Zech
Journal:  J Biol Chem       Date:  1984-01-10       Impact factor: 5.157

4.  Structure and biosynthesis of cytoplasmic and secreted variants of gelsolin.

Authors:  H L Yin; D J Kwiatkowski; J E Mole; F S Cole
Journal:  J Biol Chem       Date:  1984-04-25       Impact factor: 5.157

5.  Purification of fibronectin from human plasma by affinity chromatography under non-denaturing conditions.

Authors:  M Vuento; A Vaheri
Journal:  Biochem J       Date:  1979-11-01       Impact factor: 3.857

6.  Actin affinity chromatography in the purification of human, avian and other mammalian plasma proteins binding vitamin D and its metabolites (Gc globulins).

Authors:  J G Haddad; M A Kowalski; J W Sanger
Journal:  Biochem J       Date:  1984-03-15       Impact factor: 3.857

7.  An actin-destabilizing factor is present in human plasma.

Authors:  C Chaponnier; R Borgia; E Rungger-Brändle; R Weil; G Gabbiani
Journal:  Experientia       Date:  1979-08-15

8.  Fixation of human anti-actin autoantibodies on skeletal muscle fibres.

Authors:  C Chaponnier; L Kohler; G Gabbiani
Journal:  Clin Exp Immunol       Date:  1977-02       Impact factor: 4.330

9.  Further characterization of the Ca2+-dependent F-actin-depolymerizing protein of human serum.

Authors:  R Thorstensson; G Utter; R Norberg
Journal:  Eur J Biochem       Date:  1982-08

10.  Vitamin D-binding protein (Gc-globulin) binds actin.

Authors:  H Van Baelen; R Bouillon; P De Moor
Journal:  J Biol Chem       Date:  1980-03-25       Impact factor: 5.157

View more
  50 in total

1.  Uptake and degradation of filamentous actin and vitamin D-binding protein in the rat.

Authors:  S Dueland; M S Nenseter; C A Drevon
Journal:  Biochem J       Date:  1991-02-15       Impact factor: 3.857

2.  Circulating actin-gelsolin complexes following oleic acid-induced lung injury.

Authors:  D B Smith; P A Janmey; S E Lind
Journal:  Am J Pathol       Date:  1988-02       Impact factor: 4.307

3.  1,25-Dihydroxycholecalciferol inhibits the cochemotactic activity of Gc (vitamin D binding protein).

Authors:  M Petrini; A Azzarà; G Carulli; B Grassi; F Ambrogi; R M Galbraith
Journal:  J Endocrinol Invest       Date:  1991-05       Impact factor: 4.256

4.  Role of group-specific component (vitamin D binding protein) in clearance of actin from the circulation in the rabbit.

Authors:  P J Goldschmidt-Clermont; H Van Baelen; R Bouillon; T E Shook; M H Williams; A E Nel; R M Galbraith
Journal:  J Clin Invest       Date:  1988-05       Impact factor: 14.808

5.  Uptake and degradation of vitamin D binding protein and vitamin D binding protein-actin complex in vivo in the rat.

Authors:  S Dueland; R Blomhoff; J I Pedersen
Journal:  Biochem J       Date:  1990-05-01       Impact factor: 3.857

6.  Maternal serum proteome changes between the first and third trimester of pregnancy in rural southern Nepal.

Authors:  P F Scholl; R N Cole; I Ruczinski; M Gucek; R Diez; A Rennie; C Nathasingh; K Schulze; P Christian; J D Yager; J D Groopman; K P West
Journal:  Placenta       Date:  2012-03-03       Impact factor: 3.481

7.  Gelsolin decreases actin toxicity and inflammation in murine multiple sclerosis.

Authors:  Kevin Li-ChunHsieh; Stefan Schob; Matthias W G Zeller; Benjamin Pulli; Muhammad Ali; Cuihua Wang; Terry Ting-Yu Chiou; Yuk-Ming Tsang; Po-Shun Lee; Thomas P Stossel; John W Chen
Journal:  J Neuroimmunol       Date:  2015-08-09       Impact factor: 3.478

8.  Gelsolin is depleted in post-shock mesenteric lymph.

Authors:  Janeen R Jordan; Ernest E Moore; Sagar S Damle; Phillip Eckels; Jeffrey L Johnson; Jonathan P Roach; Jasmina S Redzic; Kirk C Hansen; Anirban Banerjee
Journal:  J Surg Res       Date:  2007-11       Impact factor: 2.192

9.  A direct interaction with calponin inhibits the actin-nucleating activity of gelsolin.

Authors:  Imen Ferjani; Abdellatif Fattoum; Sutherland K Maciver; Christine Bénistant; Anne Chahinian; Mohamed Manai; Yves Benyamin; Claude Roustan
Journal:  Biochem J       Date:  2006-06-15       Impact factor: 3.857

10.  Hypogelsolinemia, a disorder of the extracellular actin scavenger system, in patients with multiple sclerosis.

Authors:  Alina Kułakowska; Nicholas J Ciccarelli; Qi Wen; Barbara Mroczko; Wiesław Drozdowski; Maciej Szmitkowski; Paul A Janmey; Robert Bucki
Journal:  BMC Neurol       Date:  2010-11-01       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.